Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide

Endocrine Journal

Volumn 54, Issue 3, 2007, Pages 459-464

  Yetkin, Demet Ozgil ^a   Boysan, Serife Nur ^a   Tiryakioglu, Ozay ^a   Yalin, Ayse Serap ^a   Kadioglu, Pinar ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Acromegaly; Long term treatment; Sandostatin LAR

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; CHOLECYSTECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; GALLSTONE; HUMAN; HYPOPHYSIS ADENOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; OCTREOTIDE; SALVAGE THERAPY; SOMATOSTATIN; TREATMENT FAILURE;

EID: 34547112051     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-100     Document Type: Article

References (26)

1. Melmed S (1990) Acromegaly. N Engl J Med 322: 966-977.
2. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85: 526-529.
3. th ed. Lange McGraw-Hill 155-160.
4. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Drug therapy: octreotide. N Engl J Med 334: 246-254.
5. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87: 3013-3018.
6. Gillis JC, Noble S, Goa KL (1997) Octreotide long acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 53: 681-699.
7. Bastard JP (1997) A simple index of insulin resistance. Diabetes Metab 23: 87-88.
8. Tiryakioglu O, Kadioglu P, Caneroglu NU, Hatemi H (2003) Age dependency of serum insulin-like growth factor (IGF)-1 in healthy Turkish adolescents and adults. Indian J Med Sci 57: 543-548.
9. Lundin P, Peterson F Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 16: 519-528.
10. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003) Four year treatment with octreotide long acting repeatable in 110 acromegalic patients: predictive value of short term results. J Clin Endocrinol Metab 88: 3090-3098.
11. Coloa A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardini G (2001) Long term effects of depot long acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86: 2779-2786.
12. Freda PU, Katznelson L, Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005) Long acting somatostatin analog therapy of acromegaly: a meta analysis. J Clin Endocrinol Metab 90: 4465-4473.
13. Lancranjan I, Atkinson AB, and the Sandostatin LAR group (1999) Results of European multicenter study with Sandostatin LAR in acromegalic patients. Pituitary 1: 105-114.
14. Steward I, Kane FK, Steward SE, Lancranian I, Scheppard MC (1995) Depot long acting somatostatin analog Sandostatin LAR is an effective treatment for acromegaly. J Clin Endocrinol Metab 80: 3267-3272.
15. Wass JAH (1997) Growth hormone, insulin like growth factor 1 and its binding proteins in the follow up of acromegaly. J Endocrinol 155 (Suppl): S17-19.
16. Monteras ALE, Mercado M, Sosa E, Lizamo O, Guinto G, Lopez-Felix B, Garcia O, Hernandez I, Ovalle A, Mendoza V (2002) Changing patterns of insulin like growth factor-1 and glucose suppressed growth hormone levels after pituitary surgery in patients with acromegaly. J Neurosurg 97: 287-292.
17. Peacey SR, Shalet SM (1999) Growth hormone pulsatility in acromegaly following radiotherapy. Pituitary 2: 63-69.
18. Freda PU, Post KD, Powell JS, Wardlaw SL (1998) Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 83: 3808-3816.
19. Colao A, Pivonello R, Cappabianca P, Brigani F, Tortara F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G (2005) Effect of gender and gonadal status on long term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol 63: 342-349.
20. Gilbert J, Ketchen M, Kane P, Mason T, Baister E, Monaghan M, Barr S, Harris PE (2003) The treatment of de novo acromegalic patients with octreotide LAR: efficacy, tolerability and cardiovascular events. Pituitary 6: 11-18.
21. Ronchi CL, Orsi E, Giavoli C, Cappiello V, Epaminonda P, Peccoz P, Arosio M (2003) Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest 26: 533-538.
22. Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T (2006) Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage. Endocrine Journal 53: 125-132.
23. Plockinger U, Reichel M, Fett U, Saeger W, Quabbe HJ (1994) Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 79: 1416-1423.
24. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Guistina A, Carella C (2002) Long term effects of lanreotide SR, and octreotide LAR on tumor shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56: 65-71.
25. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G (2006) Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91: 2112-2118.
26. Turner HE, Lindsell RDM, Vadivale A, Thillanayagam AV, Wass AH (1999) Differing effects on gall bladder motility of lanreotide-SR and octreotide LAR for treatment of acromegaly. Eur J Endocrinol 141: 590-594.